Ulrik S. Sorensen - Publications

NaV1.5 or KCa2 channel blockade does not increase arrhythmia risk in hypokalemic rabbit hearts, unlike KV11.1 inhibition with dofetilide.

Journal: International journal of cardiology. Heart & vasculature

Published: March 27, 2025

Analysis of drug-induced and spontaneous cardioversions reveals similar patterns leading to termination of atrial fibrillation.

Journal: Frontiers in physiology

Published: March 11, 2024

Inhibition of the KCa2 potassium channel in atrial fibrillation: a randomized phase 2 trial.

Journal: Nature medicine

Published: June 15, 2023

A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation.

Journal: British journal of clinical pharmacology

Published: July 05, 2022

Increased fibroblast accumulation in the equine heart following persistent atrial fibrillation.

Journal: International journal of cardiology. Heart & vasculature

Published: January 06, 2021

Effective termination of atrial fibrillation by SK channel inhibition is associated with a sudden organization of fibrillatory conduction.

Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Published: November 04, 2020

Inhibition of Small-Conductance Calcium-Activated Potassium Current (I K,Ca) Leads to Differential Atrial Electrophysiological Effects in a Horse Model of Persistent Atrial Fibrillation.

Journal: Frontiers in physiology

Published: October 06, 2020

Inhibition of KCa2 Channels Decreased the Risk of Ventricular Arrhythmia in the Guinea Pig Heart During Induced Hypokalemia.

Journal: Frontiers in pharmacology

Published: February 26, 2020

First Clinical Study with AP30663 - a KCa 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation.

Journal: Clinical and translational science

Published: February 26, 2020

The KCa2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs.

Journal: Frontiers in pharmacology

Published: December 16, 2019

Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.

Journal: Frontiers in pharmacology

Published: December 16, 2019

Arrhythmia development during inhibition of small-conductance calcium-activated potassium channels in acute myocardial infarction in a porcine model.

Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Published: April 19, 2019